A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Status: Open to Accrual

Learn more: 

• clinicaltrials.gov: #NCT04427293

Study Contact: studies@hoosiercancer.org; (317) 921-2050.